Skip to content
MarketScale
‹ Back to IndustriesSciences

This Season’s Mission Will Be Making Space Relatable

Space to Grow is back for a second season with hosts Chris Blackerby and Charity Weeden from Astroscale. It’s where economics, technology and sustainability in space intersect. In the opening episode, Blackerby and Weeden take a look back and forward regarding the space economy. “We’re going to focus a lot on partnerships as a dedicated…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · AstroscaleJames Webb Space TelescopePartnershipsPolicy
Share

Key takeaways

01

Space to Grow is back for a second season with hosts Chris Blackerby and Charity Weeden from Astroscale.

02

It’s where economics, technology and sustainability in space intersect.

03

In the opening episode, Blackerby and Weeden take a look back and forward regarding the space economy.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Space to Grow is back for a second season with hosts Chris Blackerby and Charity Weeden from Astroscale. It’s where economics, technology and sustainability in space intersect. In the opening episode, Blackerby and Weeden take a look back and forward regarding the space economy.

“We’re going to focus a lot on partnerships as a dedicated theme of conversations, as they are driving the space economy,” Blackerby said.

Since space exploration and sustainability are such complex initiatives, partnerships are critical.

Blackerby and Weeden shared some big moments in space from the last year. “Even with COVID, it was an incredible year for space,” Blackerby noted.

Weeden’s top moment was humanity in space. “Private citizens went into space. That’s a first, and everyone can relate to that.”

While that was a pivotal moment, others demonstrated risks and challenges, spawning from geopolitical impacts on Earth. One of those is the Russian ASAT (anti-satellite weapon) tests.

Turning back to good news that demonstrates cooperation and collaboration, the James Webb Space Telescope launched through a partnership between the U.S. and Europe. Weeden relayed that the investment in the space economy isn’t slowing in other good news. It’s actually growing.

The hosts then provided a preview of what’s to come this season. They’ll welcome a diverse group of guests from around the world. Topics will range from business to policy to technology.

Weeden also announced a new segment Space to Grow After Hours. “We’ll be debating topics with the pros and cons in this extra content,” she described.

More in This Series

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech is investing $750 million in a new fill-finish plant in Hillsboro. The facility will focus on the production of prefilled syringes and autoinjectors. The site is expected to become operational in 2031.

  • 01Genentech is investing $750 million in a new Hillsboro facility.
  • 02The facility will produce prefilled syringes and autoinjectors.
  • 03Operations at the plant are expected to begin in 2031.

Aug 27, 2026

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio's cell-free hpDNA will be used by Genezen as starting material for viral vectors, potentially reducing the need for AAV input DNA by 30%. This innovation may lead to changes in the specification of plasmids and project timelines in gene therapy programs.

  • 01Genezen will utilize 4basebio’s cell-free hpDNA for viral vector production.
  • 02This approach could reduce AAV input DNA requirements by 30%.
  • 03The adoption of hpDNA could lead to changes in plasmid specification and project timelines.

Aug 27, 2026

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers has terminated its agreement with Cellares, which raises concerns about the standardized capacity for cell therapy production. This decision highlights the importance of aligning manufacturing processes with production capabilities, rather than merely focusing on the availability of factory slots.

  • 01Bristol Myers has terminated its agreement with Cellares, affecting cell therapy capacity.
  • 02Aligning process fit with production capabilities is crucial for cell therapy success.
  • 03Factory slots alone are not sufficient to ensure supply plans in cell therapy production.

Aug 26, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512